These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 33154164)
1. SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1. Wang JQ; Lin ZC; Li LL; Zhang SF; Li WH; Liu W; Song BL; Luo J J Biol Chem; 2021; 296():100032. PubMed ID: 33154164 [TBL] [Abstract][Full Text] [Related]
2. The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL. Nelson JK; Sorrentino V; Avagliano Trezza R; Heride C; Urbe S; Distel B; Zelcer N Circ Res; 2016 Feb; 118(3):410-9. PubMed ID: 26666640 [TBL] [Abstract][Full Text] [Related]
3. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor. Sorrentino V; Zelcer N Curr Opin Lipidol; 2012 Jun; 23(3):213-219. PubMed ID: 22510808 [TBL] [Abstract][Full Text] [Related]
4. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL). Sorrentino V; Scheer L; Santos A; Reits E; Bleijlevens B; Zelcer N J Biol Chem; 2011 Aug; 286(34):30190-9. PubMed ID: 21734303 [TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate-binding site. Martinelli L; Adamopoulos A; Johansson P; Wan PT; Gunnarsson J; Guo H; Boyd H; Zelcer N; Sixma TK J Biol Chem; 2020 Sep; 295(39):13570-13583. PubMed ID: 32727844 [TBL] [Abstract][Full Text] [Related]
6. The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation. Sorrentino V; Nelson JK; Maspero E; Marques ARA; Scheer L; Polo S; Zelcer N J Lipid Res; 2013 Aug; 54(8):2174-2184. PubMed ID: 23733886 [TBL] [Abstract][Full Text] [Related]
7. IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor. Scotti E; Calamai M; Goulbourne CN; Zhang L; Hong C; Lin RR; Choi J; Pilch PF; Fong LG; Zou P; Ting AY; Pavone FS; Young SG; Tontonoz P Mol Cell Biol; 2013 Apr; 33(8):1503-14. PubMed ID: 23382078 [TBL] [Abstract][Full Text] [Related]
8. IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia. Zhang CP; Tian Y; Zhang M; Tuo QH; Chen JX; Liao DF Med Hypotheses; 2016 Jan; 86():138-42. PubMed ID: 26601593 [TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Scotti E; Hong C; Yoshinaga Y; Tu Y; Hu Y; Zelcer N; Boyadjian R; de Jong PJ; Young SG; Fong LG; Tontonoz P Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340 [TBL] [Abstract][Full Text] [Related]
10. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. Hong C; Duit S; Jalonen P; Out R; Scheer L; Sorrentino V; Boyadjian R; Rodenburg KW; Foley E; Korhonen L; Lindholm D; Nimpf J; van Berkel TJ; Tontonoz P; Zelcer N J Biol Chem; 2010 Jun; 285(26):19720-6. PubMed ID: 20427281 [TBL] [Abstract][Full Text] [Related]
11. Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake. Nelson JK; Cook EC; Loregger A; Hoeksema MA; Scheij S; Kovacevic I; Hordijk PL; Ovaa H; Zelcer N J Biol Chem; 2016 Feb; 291(9):4813-25. PubMed ID: 26719329 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). Do HT; Tselykh TV; Mäkelä J; Ho TH; Olkkonen VM; Bornhauser BC; Korhonen L; Zelcer N; Lindholm D J Biol Chem; 2012 Apr; 287(16):12602-11. PubMed ID: 22378787 [TBL] [Abstract][Full Text] [Related]
13. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Zhang L; Reue K; Fong LG; Young SG; Tontonoz P Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2541-6. PubMed ID: 22936343 [TBL] [Abstract][Full Text] [Related]
14. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Zelcer N; Hong C; Boyadjian R; Tontonoz P Science; 2009 Jul; 325(5936):100-4. PubMed ID: 19520913 [TBL] [Abstract][Full Text] [Related]
15. Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol. Ibrahim S; Somanathan S; Billheimer J; Wilson JM; Rader DJ Cardiovasc Res; 2016 May; 110(1):23-9. PubMed ID: 26786161 [TBL] [Abstract][Full Text] [Related]
16. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Zhang L; Fairall L; Goult BT; Calkin AC; Hong C; Millard CJ; Tontonoz P; Schwabe JW Genes Dev; 2011 Jun; 25(12):1262-74. PubMed ID: 21685362 [TBL] [Abstract][Full Text] [Related]
17. The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease. van Loon NM; Lindholm D; Zelcer N Curr Opin Lipidol; 2019 Jun; 30(3):192-197. PubMed ID: 30896554 [TBL] [Abstract][Full Text] [Related]
18. FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Calkin AC; Goult BT; Zhang L; Fairall L; Hong C; Schwabe JW; Tontonoz P Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20107-12. PubMed ID: 22109552 [TBL] [Abstract][Full Text] [Related]
19. IDOL G51S Variant Is Associated With High Blood Cholesterol and Increases Low-Density Lipoprotein Receptor Degradation. Adi D; Lu XY; Fu ZY; Wei J; Baituola G; Meng YJ; Zhou YX; Hu A; Wang JK; Lu XF; Wang Y; Song BL; Ma YT; Luo J Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2468-2479. PubMed ID: 31597442 [TBL] [Abstract][Full Text] [Related]
20. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]